Lomustine

  • Belustine
  • n-(2-Chloroethyl)-N'-cyclohexyl-n-nitrosourea
  • 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea
Formula
C9H16ClN3O2
Structure
Description
Yellow powder.
Uses
Medication.

Registry Numbers and Inventories.
CAS
13010-47-4
EC (EINECS/ELINCS)
235-859-2
RTECS
YS4900000
RTECS class
Tumorigen; Drug; Mutagen; Reproductive Effector; Human Data
Merck
12,5594
Beilstein/Gmelin
2125058
Austrailia AICS
Listed

Properties.
Formula
C9H16ClN3O2
Formula mass
233.7
Melting point, °C
90
Solubility in water
practically insoluble

Hazards and Protection.
Storage
Keep in a cool, dry, dark location in a tightly sealed container or cylinder. Keep away from incompatible materials, ignition sources and untrained individuals. Secure and label area. Protect containers/cylinders from physical damage.
Handling
All chemicals should be considered hazardous. Avoid direct physical contact. Use appropriate, approved safety equipment. Untrained individuals should not handle this chemical or its container. Handling should occur in a chemical fume hood.
Protection
Chemical splash goggles in compliance with OSHA regulations are advised; however, OSHA regulations also permit other type safety glasses. Whre chemical resistant gloves. To prevent repeated or prolonged skin contact, wear impervious clothing and boots.
Respirators
Use NIOSH/MSHA approved respirator appropriate for exposure of concern.
Small spills/leaks
Evacuate area and ventilate. Wear protective equipment. If required, use an inert absrobent. Sweep up and place in an appropriate container for disposal. Wash contaminated surfaces.
Stability
No data.
Incompatibilities
Strong oxidizing agents.

Fire.
Fire fighting
Wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Use agent most appropriate to extinguish fire.

Health.
Carcinogin
I-2A, N-2, CP65
Exposure effects
CNS depression may occur. Use during pregnancy or while breast-feeding should be avoided.
   Ingestion
Nausea and vomiting may occur.
   Inhalation
Dose related pulmonary infiltration or fibrosis has been reported as a delayed adverse effect.
   Skin
Skin irritation may occur.

First aid
 
   Ingestion
Seek medical attention. If individual is drowsy or unconscious, do not give anything by mouth; place individual on the left side with the head down. Contact a physician, medical facility, or poison control center for advice about whether to induce vomiting. If possible, do not leave individual unattended.
   Inhalation
If symptoms develop, move individual away from exposure and into fresh air. If symptoms persist, seek medical attention. If breathing is difficult, administer oxygen. Keep person warm and quiet; seek immediate medical attention.
   Skin
Flush skin with plenty of soap and water for at least 15 minutes while removing contaminated clothing and shoes.
   Eyes
Irrigate exposed eyes with copious amounts of tepid water for at least 15 minutes. If irritation, pain, swelling, lacrimation, or photophobia persist, the patient should be seen in a health care facility.

Transport.